We are live on ! Find out more
RGNX icon

Regenxbio

187 hedge funds and large institutions have $1.23B invested in Regenxbio in 2019 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 64 increasing their positions, 53 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 9

150% more funds holding in top 10

Funds holding in top 10: 25 (+3)

21% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 53

18% more capital invested

Capital invested by funds: $1.04B → $1.23B (+$190M)

11% more funds holding

Funds holding: 168187 (+19)

2.04% more ownership

Funds ownership: 79.46%81.5% (+2%)

32% less call options, than puts

Call options by funds: $8.09M | Put options by funds: $11.9M

Holders
187
Holders Change
+19
Holders Change %
+11.31%
% of All Funds
3.67%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.1%
New
33
Increased
64
Reduced
53
Closed
9
Calls
$8.09M
Puts
$11.9M
Net Calls
-$3.83M
Net Calls Change
-$5.16M

RGNX Hedge Fund Activity: Q4 2019 in Review

187 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2019, worth a combined $1.23B — up 18% from $1.04B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new RGNX positions and 9 closed out — a net gain of 24 holders — while 64 added to existing stakes and 53 trimmed.

The largest buyer was Aquilo Capital Management, opening a new position worth an estimated $10.6M. The largest seller was Carmignac Gestion, cutting an estimated $37.7M.

  • 187 institutional investors held Regenxbio (RGNX) as of Q4 2019, up from 168 in Q3 2019.
  • Funds reported $1.23B of Regenxbio stock for Q4 2019, up 18% quarter-over-quarter.
  • 33 funds opened new Regenxbio positions in Q4 2019 and 9 closed out, a net change of +24 holders.
  • The largest Regenxbio buyer in Q4 2019 was Aquilo Capital Management, an estimated $10.6M added.
  • The largest Regenxbio seller in Q4 2019 was Carmignac Gestion, an estimated $37.7M sold.

Based on aggregated 13F filings for Q4 2019.